Evidence map›Paper›PMID 39673602›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Exploration of (R)-[

Yingfang He, MingQiang Zheng, Jiwei Gu, Lisa Reichert, Johannes Trimborn, Hui Zhang, Claudia Keller, Mallory Crosby, Ludovic Collin, Dominik Heer and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects.European journal of nuclear medicine and molecular imaging · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yingfang He *Center for Radiopharmaceutical Sciences, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, CH-8093, Switzerland.
MingQiang Zheng *Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA.
Jiwei GuYale PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA.
Lisa ReichertCenter for Radiopharmaceutical Sciences, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, CH-8093, Switzerland.
Johannes TrimbornCenter for Radiopharmaceutical Sciences, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, CH-8093, Switzerland.
Hui ZhangYale PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA.
Claudia KellerCenter for Radiopharmaceutical Sciences, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, CH-8093, Switzerland.
Mallory CrosbyYale PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA.
Ludovic CollinPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, CH-4070, Switzerland.
Dominik HeerPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, CH-4070, Switzerland.
Anto PavlovicPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, CH-4070, Switzerland.
Andreas ToppPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, CH-4070, Switzerland.
Matthias Beat WittwerPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, CH-4070, Switzerland.ORCID 0000-0003-1359-4795
Uwe GretherPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, CH-4070, Switzerland.
Luca GobbiPharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, CH-4070, Switzerland.
Roger SchibliCenter for Radiopharmaceutical Sciences, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, CH-8093, Switzerland.
Yiyun HuangYale PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA. henry.huang@yale.edu.
Linjing MuCenter for Radiopharmaceutical Sciences, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, CH-8093, Switzerland. linjing.mu@pharma.ethz.ch.ORCID 0000-0001-5354-1546

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

purposeThe monoacylglycerol lipase (MAGL) plays a pivotal role in modulating the endocannabinoid system and is considered an attractive therapeutic target for diseases in both the central nervous system and periphery. The current study aimed to develop and evaluate a suitable carbon-11 labeled tracer for imaging MAGL in preclinical studies.

methods(R)-YH168 was synthesized via a multi-step pathway and its half-maximal inhibitory concentration (IC

results(R)-[

conclusion(R)-[

Indexed as

BrainCarbon RadioisotopesMonoacylglycerol LipasesPositron-Emission TomographyRadiopharmaceuticalsAnimalsMacaca mulattaMaleMiceRadioactive TracersTissue DistributionCarbon-11Carbon RadioisotopesMonoacylglycerol LipasesRadioactive TracersRadiopharmaceuticalsCarbon-11Drug developmentMonoacylglycerol lipaseNeuroimaging

Identifiers

PMID39673602
PMCPMC11839854

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.